Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
HIV Clinical Trials|October 27, 2010
Simplification from protease inhibitors to once- or twice-daily raltegravir: the ODIS trialEugenia Vispo, Pablo Barreiro, Ivana Maida, et al.
Journal of Medical Virology|February 11, 2018
Prevalence of NS5A resistance associated substitutions in patients with hepatitis C virus genotypes 1a and 3: Impact on current therapeutic strategiesMarta Grandal, Berta Pernas, Andrés Tabernilla, et al.
AIDS (London, England)|May 15, 2013
Influence of HIV infection on response to tenofovir in patients with chronic hepatitis BZulema Plaza, Antonio Aguilera, Alvaro Mena, et al.
AIDS (London, England)|May 30, 2014
High prevalence of subtype F in newly diagnosed HIV-1 persons in northwest Spain and evidence for impaired treatment responseBerta Pernas, Marta Grandal, Alvaro Mena, et al.
AIDS Patient Care and Stds|April 9, 2021
Reasons for Choice of Antiretroviral Regimens in HIV Patients Presenting Late for Initial Treatment in EuropeGundolf Schuettfort, Alfonso Cabello, Aoife G Cotter, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|June 4, 2016
Brief Report: European Mitochondrial Haplogroups Impact on Liver Fibrosis Progression Among HCV and HIV/HCV-Coinfected Patients From Northwest SpainAndres Tabernilla, Ignacio Rego-Pérez, Marta Grandal, et al.
Open Forum Infectious Diseases|April 6, 2019
Predictors of Hepatitis C Treatment Failure After Using Direct-Acting Antivirals in People Living With Human Immunodeficiency VirusEdward R Cachay, Alvaro Mena, Luis Morano, et al.
Journal of Clinical Medicine|September 14, 2024
Cyclosporin A as an Add-On Therapy to a Corticosteroid-Based Background Treatment in Patients with COVID-19: A Multicenter, Randomized Clinical TrialLucía Llanos Jiménez, Beatriz Alvarez-Alvarez, Eva Fonseca Aizpuru, et al.
International Journal of Antimicrobial Agents|April 29, 2026
Safety and tolerability of switching to bictegravir/emtricitabine/tenofovir alafenamide versus continuing dolutegravir/lamivudine in people living with HIV with neuropsychiatric comorbidities: week 24 and 48 results from the Management of INSTI-associated Neuropsychiatric Disorders (MIND) clinical trialIgnacio Perez-Valero, Diana Corona Mata, María Jose Crussells Canales, et al.
Pageof 2